Home / About us / Mission and values

Our mission and values

We are a lean, fully integrated CRO specializing in rare diseases, with the expertise and continuity to de-risk, protect and progress your program.

Connecting patient needs with rigorous science 

AGADA’s mission is to accelerate drug development by providing expert guidance in surrogate biomarkers and outcomes. We support sponsors in making informed drug development decisions by applying a depth of knowledge, robust experimental design, data generation and data interpretation to their preclinical and clinical projects and trials.

We strive to bring therapies for rare diseases to patients faster because every study, every data point and every program makes a real difference. We design every step of your study with rare disease realities in mind, connecting patient needs with strict regulatory expectations.

Our values

Our values reflect how we work together and how we support our clients: with rigor, respect, collaboration and a commitment to doing the work well. They continue to be shaped by our team and grounded in the standards we set for ourselves every day.

Scientific integrity and quality:

We apply disciplined execution and established standard operating procedures to protect your data and ensure your clinical endpoints withstand rigorous agency scrutiny.

Practical collaboration:

We work as an extension of your team, providing direct access to senior scientists and shaping our support around the specific needs of your rare disease program.

Patient-centered resolve:

We maintain an unwavering focus on the ultimate goal, utilizing our specialized expertise to help promising therapies reach the patients who need them.

Discuss your program needs

Engage our senior scientists to see how our values translate into dependable execution for your rare disease program.

Putting our values into practice

We put our values into practice through disciplined execution and a collaborative approach. Our lean model keeps senior scientific expertise close to the work and removes unnecessary red tape, enabling decisions to be made quickly and transparently. We maintain rigorous standard operating procedures to ensure every choice we make protects the integrity of your rare disease program and honors our commitment to patient needs.

Meet our leadership team

Eric Hoffman, PhD

Co-founder, CEO

Learn more

Kanneboyina Nagaraju, DVM, PhD

Co-founder and Board Member

Learn more

Amanda Mullen, BSc, MBA

Chief Operating Officer

Learn more

Pia Elustondo, PhD

Senior Director of Research

Learn more